Skip to main content

Table 2 Immunohistochemical MQSs (0–8) for p14ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive ductal cancer and ductal carcinoma in situ

From: p14ARF expression in invasive breast cancers and ductal carcinoma in situ– relationships to p53 and Hdm2

Protein Cancer type Location Tumour no. (%) MQS 0–2 (0) MQS 3–5 (1+) MQS 6–8 (2+)
p14ARF Invasive Nucleus 96 20 (21) 31 (32) 45 (47)
   Cytoplasm 95 72 (76) 16 (17) 7 (7)
  DCIS Nucleus 91 17 (17) 29 (32) 45 (49)
   Cytoplasm 91 70 (80) 13 (14) 8 (9)
p53 Invasive Nucleus 93 62 (67) 17 (18) 14 (15)
   Cytoplasm 93 70 (75) 18 (19) 5 (5)
  DCIS Nucleus 91 66 (73) 12 (13) 13 (14)
   Cytoplasm 91 58 (62) 27 (29) 6 (6)
Hdm2 Invasive Nucleus 92 49 (53) 33 (36) 10 (11)
   Cytoplasm 91 42 (46) 33 (36) 16 (18)
  DCIS Nucleus 91 51 (56) 25 (27) 15 (16)
   Cytoplasm 91 43 (47) 27 (30) 21 (23)
  1. Tumour numbers scored (MQS 0–8) by immunohistochemistry for p14ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive cancers and ductal carcinoma in situ (DCIS) are shown. Immunohistochemistry expression was assessed individually in the nucleus and the cytoplasm, and is defined as negative (0) (MQS 0–2), weak/moderate (1+) (MQS 3–5) and strong (2+) (MQS 6–8). Positivity for p14ARF, p53 and Hdm2 expression was defined as an MQS of 3 or more (1+/2+).